Santander

• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 9 2020-10-05 Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
• Pan tumor Roll Over Study Recruiting
  2023-506914-32-00 4 2020-05-05 Pan tumor
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 4 2019-05-07 Locally Advanced/Metastatic Urothelial Cancer
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 10 2018-12-21 Defined by parent protocol. The study will enroll all adult and paedia
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Ended recruitment
  2024-511101-28-00 4 2026-02-24 Episodic Migraine Chronic Migraine
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• A clinical study of sotatercept in people with pulmonary arterial hypertension (MK-7962-038) Ended recruitment
  2025-521970-33-00 5 2025-12-19 ​​Pulmonary Arterial Hypertension (PAH)
• SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease Ended recruitment
  2025-521791-63-00 4 2025-12-18 Moderately to Severely Active Rheumatologic Disease
• A clinical study of tulisokibart in people with rheumatoid arthritis (MK-7240-014) Ended recruitment
  2025-521745-25-00 4 2025-11-06 Rheumatoid Arthritis
• Master protocol of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophagea … Ended recruitment
  2024-516909-23-00 4 2025-10-28 Locally Advanced Resectable Gastroesophageal Adenocarcinoma
• A Phase 3 Trial Comparing Whether BEM/RZR is Similar to SOF/VEL in Patients with Hepatitis C Virus Infection Ended recruitment
  2025-521096-31-00 5 2025-10-02 Chronic Hepatitis C Virus (HCV) Infection
• A Study to Compare Different Doses of RO7795081 with a Placebo or Semaglutide in People with Type 2 Diabetes Ended recruitment
  2024-520322-11-00 4 2025-09-29 Type 2 Diabetes Mellitus (T2D)
• Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease Ended recruitment
  2024-516295-14-00 4 2025-09-17 Treatment of Sjögren’s disease
• Proof of Concept trial with CIT-013 in Rheumatoid Arthritis Ended recruitment
  2024-517356-35-00 4 2025-07-29 Moderately Active Rheumatoid Arthritis
• A Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection Ended recruitment
  2024-520062-54-00 4 2025-07-23 Chronic Hepatitis D Virus (HDV) Infection
• A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide Ended recruitment
  2024-519282-22-00 5 2025-07-09 Chronic Hepatitis D Virus (HDV) Infection
• A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Ended recruitment
  2024-518339-12-00 4 2025-07-08 Idiopathic Pulmonary Fibrosis
• A Trial to Study the Safety and Efficacy of a New Drug Combination for Weight Loss While Maintaining Muscles Ended recruitment
  2024-519561-22-00 4 2025-07-07 Obesity
• A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m … Ended recruitment
  2024-517020-18-00 4 2025-06-30 Newly diagnosed multiple myeloma according to IMWG criteria
• A Study of Tirzepatide (LY3298176) Compared with Placebo in Adults with Type 1 Diabetes and Obesity or Overweight (SURPASS-T1D-1) Ended recruitment
  2024-519684-17-00 5 2025-06-23 Obesity
• A clinical study of sotatercept in people with pulmonary arterial hypertension Ended recruitment
  2024-518687-12-00 4 2025-06-19 Pulmonary Arterial Hypertension (PAH)
• PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended recruitment
  2024-514163-26-00 4 2025-06-09 Advanced Melanoma

Showing 265–288 of 601 trials